Mineralys Therapeutics (MLYS) Income from Continuing Operations (2022 - 2026)

Mineralys Therapeutics has reported Income from Continuing Operations for 5 years, with the latest figure at 45340000.0 in Q1 2026.

• Quarterly Income from Continuing Operations fell 2.01% year-over-year to 45340000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 317818000.0 (down 12.93% YoY) and the FY2025 annual result came in at 316925000.0, down 16.37% from the prior year.
• Income from Continuing Operations rose to 45340000.0 in Q1 2026 per MLYS's latest filing, from 184601000.0 in the prior quarter.
• Over five years, Income from Continuing Operations peaked at 6479000.0 in Q2 2022 and troughed at 184601000.0 in Q4 2025.
• A 5-year average of 44221941.18 and a median of 35362000.0 in 2024 frame the typical range for Income from Continuing Operations.
• The sharpest annual moves came in 2024 and 2025: Income from Continuing Operations sank 360.99% in 2024, then jumped 31.57% in 2025.
• Over 5 years, Income from Continuing Operations stood at 10191000.0 in 2022, then tumbled by 180.33% to 28568000.0 in 2023, then tumbled by 360.99% to 131696000.0 in 2024, then tumbled by 40.17% to 184601000.0 in 2025, then surged by 75.44% to 45340000.0 in 2026.
• According to Business Quant data, Income from Continuing Operations over the past three periods registered 45340000.0, 184601000.0, and 41131000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.